Physician profile
Mark Blair
NPI 1508869561
$4,925.61
in general payments reported to CMS, 2019-2025
37 companies · $3,077 in 2025
The $3,077 reported for 2025 was more than what 86% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $845 · 2020: $21.75 · 2021: $130 · 2022: $61.99 · 2023: $435 · 2024: $355 · 2025: $3,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,065 · Travel and Lodging: $1,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,064.98 |
| Travel and Lodging | $1,801.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,398.76 | 2021-2025 | Turbohawk, Hawkone |
| Endogastric Solutions, INC | $767.67 | 2019 | |
| Novo Nordisk INC | $294.23 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $153.20 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $118.94 | 2023-2025 | |
| Amgen INC. | $107.79 | 2023-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.40 | 2023-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $69.27 | 2022-2023 | Rexulti |
| Esperion Therapeutics, INC. | $68.61 | 2025 | Nexletol |
| Organogenesis INC. | $62.94 | 2019-2021 | |
| Axsome Therapeutics, INC. | $51.61 | 2025 | Auvelity |
| Exact Sciences Corporation | $51.47 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $50.70 | 2023-2025 | Verquvo, Belsomra |
| Ethicon US, LLC | $50.47 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.79 | 2025 | Caplyta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $43.20 | 2023-2024 | Xarelto |
| Galderma Laboratories, L.P. | $40.20 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.53 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $36.86 | 2025 | Voquezna |
| Smith+Nephew, INC. | $36.79 | 2023 | Lens 4k |
| Verity Pharmaceuticals INC. | $35.56 | 2024-2025 | Tlando |
| Stryker Corporation | $32.38 | 2025 | Molli |
| Lundbeck LLC | $29.92 | 2025 | Rexulti |
| Covidien Lp | $29.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.52 | 2025 | Jascayd |
| Paratek Pharmaceuticals, INC. | $24.61 | 2023 | Nuzyra |
| Innocoll Pharmaceuticals Limited | $20.20 | 2022 | |
| Ardelyx, INC. | $17.37 | 2025 | Ibsrela |
| Abbvie INC. | $17.14 | 2022 | |
| Shield Therapeutics INC | $16.66 | 2025 | |
| Antares Pharma, INC. | $16.64 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $16.57 | 2024 | Airsupra |
| Sumitomo Pharma America, INC. | $16.51 | 2025 | Gemtesa |
| Tolmar, INC. | $15.76 | 2025 | Jatenzo |
| Insulet Corporation | $15.44 | 2023 | Omnipod |
| Janssen Biotech, INC. | $14.04 | 2024 | Tremfya |
| Davol INC. | $13.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Blair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.